肿瘤细胞治疗研究
英文原题：Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non-small cell lung cancer: A case report.
Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non-small cell lung cancer: A case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
细胞因子释放综合征（CRS）是一种严重且危及生命的毒性反应，通常见于 CAR-T 细胞治疗，在免疫检查点抑制剂（ICI）治疗中罕有报道。
细胞因子释放综合征（CRS）是一种严重且危及生命的毒性反应，通常报道于CAR-T 细胞治疗中，在免疫检查点抑制剂（ICI）治疗中鲜有报道。本研究报道了一例75岁日本女性患者，因非小细胞肺癌术后复发接受nivolumab联合ipilimumab治疗。她因发热、低血压、肝功能障碍和血小板减少症入住我院。入院时我们观察到其颈部有轻微皮疹，数日内迅速蔓延至全身。我们诊断为CRS并伴有严重皮疹。经皮质类固醇治疗后CRS症状缓解，此后未再复发。CRS是ICI治疗相关的一种罕见但重要的免疫相关不良事件。
Cytokine release syndrome (CRS) is a severe and life-threatening toxicity typically reported in chimeric antigen receptor T cell therapy and is rarely reported in immune checkpoint inhibitor (ICI) therapy. This study reports the case of a 75-year-old Japanese woman who received nivolumab plus ipilimumab therapy for the postoperative recurrence of non-small cell lung cancer. She was admitted to our hospital with fever, hypotension, hepatic disorder, and thrombocytopenia. We observed slight skin rashes on her neck on admission, which spread rapidly across her body within a few days. We diagnosed CRS complicated by severe rashes. CRS symptoms were resolved with corticosteroid therapy, and did not recur thereafter. CRS is a rare, but important, immune-related adverse event associated with ICI therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
